Amit Etkin
@AmitEtkin
Founder & CEO of @AltoNeuro (NYSE: $ANRO). Pioneering #PrecisionPsychiatry. MD neuroscientist + PhD psychiatrist, Stanford professor.
Today @AltoNeuro began trading on the @NYSE under the ticker $ANRO. I founded Alto out of the desire to give patients better treatment options than those that are currently available. Today we take one step closer to our goal of making #PrecisionPsychiatry a reality.
The NYSE welcomes @AltoNeuro in celebration of its listing! $ANRO
Here's the link to the full interview on the @NYSE floor from last week at the AI x Bio summit. It was a pleasure to share what we are up to @AltoNeuro! A lot of exciting potential ahead. tv.nyse.com/floor-talk/sea…
Was a lot of fun sharing the @AltoNeuro story and updates on the iconic floor of the @NYSE. A lot of clinical readouts to come over the next two years!
LIVE on NYSE TV 🎙️ Hear top economic data from @commonsensebull. @AmitEtkin of @AltoNeuro shares how they are utilizing AI at NYSE hosted AI x Bio Summit. Plus, @AccelerantHQ celebrates its IPO $ARX!
LIVE on NYSE TV 🎙️ Hear top economic data from @commonsensebull. @AmitEtkin of @AltoNeuro shares how they are utilizing AI at NYSE hosted AI x Bio Summit. Plus, @AccelerantHQ celebrates its IPO $ARX!
It was a pleasure to speak with @BiotechTV today at the @NYSE!
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: The CEO of @AltoNeuro, which is working on precision medicine and enhanced patient selection for neuroscience, talks about how the company is using AI and machine learning in its development programs. Full video: biotechtv.com/post/alto-neur…
Important PAX-D publication today! I highlight the findings and how ALTO-207 builds on that success in the video below
We’re excited to highlight that data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD) were published online in The Lancet Psychiatry. Results from this study guided Alto’s acquisition of ALTO-207. Read more: investors.altoneuroscience.com/news/news-deta…
Congrats to the @OxPsychiatry team, Mike Browning and the PAX-D investigators on a landmark finding demonstrating striking efficacy of pramipexole in TRD!
📣A Parkinson’s drug, #pramipexole, shows promise for #treatmentresistantdepression. In an @oxpsych led and @NIHRresearch supported trial, patients saw major symptom relief by week 12—with effects lasting a year. Read more: tinyurl.com/pramipexoleTRD
We’re excited to highlight that data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD) were published online in The Lancet Psychiatry. Results from this study guided Alto’s acquisition of ALTO-207. Read more: investors.altoneuroscience.com/news/news-deta…
📣A Parkinson’s drug, #pramipexole, shows promise for #treatmentresistantdepression. In an @oxpsych led and @NIHRresearch supported trial, patients saw major symptom relief by week 12—with effects lasting a year. Read more: tinyurl.com/pramipexoleTRD
Today we announced the acquisition of a novel dopamine agonist portfolio, adding a late-stage readout in treatment resistant depression within our current cash runway. We’re excited for the opportunity to advance this approach! Read more: investors.altoneuroscience.com/news/news-deta…
Today, our CEO, @AmitEtkin, will participate in a panel discussion moderated by @rleuty_biotech at the Bay Area Biotech Forum, presented by @SFBusinessTimes. Learn more about the event here: bizjournals.com/sanfrancisco/e… #SFBTbiotech
Today, we reported our Q1 2025 financial results and key business highlights. Read more in our press release here: investors.altoneuroscience.com/news/news-deta… $ANRO
Our work is featured in @HCPLiveNews showcasing how an #EEG biomarker can predict placebo response in #MDD clinical trials. These findings highlight the applications of this biomarker in #ClinicalTrials and potential to advance #PrecisionPsychiatry: bit.ly/4iIyp1K